Research programme: PCSK9 protein inhibitors - Serometrix

Drug Profile

Research programme: PCSK9 protein inhibitors - Serometrix

Alternative Names: SX PCK9

Latest Information Update: 16 Mar 2015

Price : $50

At a glance

  • Originator Serometrix
  • Class Small molecules
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypercholesterolaemia

Most Recent Events

  • 16 Mar 2015 Preclinical trials in Hypercholesterolaemia in USA before March 2015 (Parenteral)
  • 16 Mar 2015 PCSK9 protein inhibitors are available for licensing as of 16 Mar 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top